Essilor has begun commercial trials in 11 UK practices of NeuroVision, a non-surgical internet-based treatment developed in Singapore that purports to improve visual performance in patients with low myopia (up to around -1.50D).
The lens maker is conducting a closed trial to assess the commercial viability of the treatment. Favourable results in clinical trials led Essilor to buy a 10 per cent equity stake in NeuroVision, as well as distribution rights in the UK, Singapore and Chicago in 2007.
Nick Hornsby, Essilor NeuroVision manager, responsible for overseeing the UK trials, commented: 'NeuroVision is an exciting and innovative treatment that complements the current services offered in any modern optical practice today. Once the results of this small commercial trial are analysed Essilor may make NeuroVision available to other practitioners who feel it would enhance their practices.'
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
